The Institut Paoli-Calmettes (IPC) Cancer Center
Based in Marseille, The Institut Paoli-Calmettes (IPC) Cancer Center has been certified Comprehensive Cancer Center by OECI (Organisation of European Cancer Institutes) in June 2019 and then in June 2024. The IPC is the first comprehensive cancer centre in the region providing cancer care. It is also a member of the national federation of Unicancer. The Institute has been licensed by the HAS (the French health authority) at the highest level in 2015.
The Centre gathers over 2,000 employees – researchers, medical doctors, health and administrative staff – engaged in wide range of activities on site: prevention, research, treatment and training. IPC registered over 100,000 consultations and over 14,000 new patients in 2023.
The Clinical Research and Innovation Direction (DRCI) has several units, including the Sponsor Unit, which coordinates the preparation, implementation and monitoring of clinical studies in oncology and onco-haematology for which the IPC is sponsor. The clinical studies sponsored by the IPC include clinical trials on medicinal products for human use (in partnership with industry), cell therapy studies, medical device studies and non-health product studies (translational research, observational studies, etc.).
As part of the ProCAncer-I project, the IPC is the only centre in France taking part in this European-funded project. The IPC has now included 444 patients out of the 450 expected, including retrospective prospective data of prostate cancer patients.
